ClinicalTrials.gg
Not yet recruitingNCT06764914NAMIKOSUpdated Jan 9, 2025

Integrative and Complementary Therapy for Episodic Migraine and Tension-type Headache

An observational study in Migraine and Headache, Tension-Type, sponsored by Kliniken Essen-Mitte. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-09.

Sponsored by Kliniken Essen-Mitte · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
130
Ages
18 Years and older
Sex
All
01

Study summary

This study is a monocentric uncontrolled observational study to evaluate a 12-14 day inpatient stay in an internal medicine clinic for integrative and complementary medicine for patients with episodic migraine and/or episodic tension headache. The aim is to investigate the extent to which a 14-day inpatient stay can influence a reduction in headache days and/or pain intensity, medication use, quality of life, anxiety, depression, perceived stress, general well-being, and a reduction in sick days/work absenteeism, and prevent the chronification of migraine and may counteract the chronification of migraine or tension-type headache. In addition, patients' previous experiences with complementary naturopathic therapies, expectations and perceived benefits in everyday life will be analysed.

Read the detailed description

Primary headache disorders are among the most common neurological disorders worldwide, with a lifetime prevalence of over 90%. Tension-type headache (TTH) is the most common type of primary headache. It manifests as a dull, pressing, tightening pain that usually 'rises' from the neck to the back of the head and down to the temples on both sides, but can theoretically occur in any part of the head. The frequency of pain attacks is used to define episodic (\< 15 days/month or \< 180 days/year) and chronic TTH (> 15 days/month for > 3 months or > 180 days/year). The main therapeutic options are classical analgesics (non-steroidal anti-inflammatory drugs, NSAIDs; Novalgin) in acute cases or tricyclic antidepressants as prevention. Prophylaxis can be combined with (endurance) exercise or acupuncture. Migraine is rarer than TTH, affecting about 9% of the population, but it is one of the most common causes of disability worldwide. It is defined as a headache with or without preceding neurological symptoms (called an aura) and occurs mainly in middle age, between 20 and 50 years. In acute attacks, migraine headaches are treated with medication (usually classic analgesics such as NSAIDs, Novalgin or migraine-specific triptans). In cases of severe distress due to frequent and severe attacks, medication may also be used as a prophylactic measure. A distinction is also made between episodic migraine (\< 15 days in the last 3 months) and chronic migraine (> 15 days/month in the last 3 months). In addition to drug therapy there are also non-drug approaches such as acupuncture, behavioural therapy, biofeedback or relaxation techniques, which may be combined with drug prophylaxis. Complications of migraine include status migraenosus (migraine attacks lasting more than 72 hours), migraine stroke and/or chronicisation of migraine. The headache disorders listed above can occur alone or in combination. When they occur together, they can severely restrict a person's daily life. According to the German Society of Neurology (DGN-Deutsche Gesellschaft für Neurologie), multimodal approaches, such as inpatient multimodal pain therapy, are explicitly recommended only in the context of chronic headache, especially chronic migraine. In addition, there are often life-limiting comorbidities, which often worsen with chronicity. The Clinic for Integrative and Complementary Medicine at the Evangelische Kliniken Essen-Mitte has been treating patients with various pain disorders for more than 20 years. Within the framework of so-called integrative care concepts with the Techniker Krankenkasse (TK) and the Barmer Ersatzkasse (BEK), headache patients are treated with naturopathic-integrative methods both as inpatients and as outpatients. The aim of this prospective observational study is to evaluate the integrative-complementary concept in patients with episodic headache (migraine and/or tension headache) without medication abuse or medication-induced headache. It will be observed whether this concept can reduce sick days/work absences, pain intensity and frequency, and medication use, thus preventing chronicity.

02

Conditions studied

  • Migraine
  • Headache, Tension-Type

Keywords

  • Migraine
  • Headache, Tension-Type
03

In context

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

This study's planned enrollment of 130 is close to the median of 138 across 332 observational studies indexed under Migraine Disorders.

Browse Migraine Disorders studies →

Lead sponsor

Kliniken Essen-Mitte is the lead sponsor of 18 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with episodic headaches (TTH and/or migraine) who choose to spend 12 to 14 days at the Clinic for Integrative and Complementary Medicine. The diagnosis must be confirmed by a neurological examination.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Episodic migraine (\<15 headache days/month in the last 3 months)
  • Episodic tension headache (\<15 headache days/month in the last 3 months)
  • Mixed forms or parallel occurrence of both types of headache is permitted
  • Diagnosis confirmed in advance by a neurologist
  • Mandatory imaging to exclude another cause of headache before or during hospitalisation (cMRI or cCT)
  • Participation in the integrative headache supply programm oft the health insurence provider Barmer Ersatzkasse and Techniker Krankenkasse
  • Signed declaration of consent

Exclusion criteria

Exclusion Criteria:

  • Age younger than 18 years
  • Chronic migraine (15 migraine days in the last 3 months) or chronic tension type headache
  • Medication-induced headache/painkiller abuse (> 10 triptans/combination analgesics/ergotamines/opiates or >15 classical analgesics per month)
  • Acute severe mental illness (e.g. severe depression with suicidal tendencies)
  • Acute, severe physical illness that prevents participation in the inpatient naturopathic programme or emergency inpatient treatment of a different kind (e.g. ongoing treatment of a cancer severe acute illness of the cardiovascular system such as heart attack, stroke, acute insufficiency of other organs (kidney, liver, etc.), other severe acute neurological diseases, e.g. relapse of multiple sclerosis, uncontrolled epilepsy)
  • Pregnancy/lactation period
  • Simultaneous participation in other clinical studies
  • No consent
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
130 participants (estimated)
Patient registry
No

Groups and cohorts

  • episodic migraine and/or episodic tension headache (tension-type headache TTH)

    Other: integrative and complementary medicine

Interventions

  • Otherintegrative and complementary medicine

    Treatment with integrative and complementary methods for both, inpatients and outpatients, includes conventional therapy, integrative methods and ordinal therapy/MBM, which are individually designed for each patient. Similar to a shedule, with therapy units from the following areas: hydrotherapy/thermotherapy, exercise therapy, physiotherapy, nutritional therapy and bodywork therapy, supplemented as required by phytotherapeutic and other therapies, such as acupuncture, neural therapy and cupping. After inpatient treatment, patients can receive up to 10 additional outpatient treatments at our TCM outpatient clinic. There is also a 10-week programme for day patients. This focuses on ordinal therapy to achieve sustainable, balanced lifestyle changes. This includes classic acupuncture and drainage techniques such as Gua Sha (connective tissue massage in TCM) or cupping, as well as neural therapy, electro-acupuncture and others. Daily medical visits and self-care advice are also included.

06

What researchers measure

Primary outcomes

  1. Number of headache days/month (headache diary);

    Time frame: 48 weeks after inpatient hospitalisation

Secondary outcomes

  1. Pain Perception Scale (PPS) using a visual analogue scale (VAS)

    The Pain Perception Scale is a tool to measure the patient's subjective assessment of symptoms, using the visual analogue scale of pain intensity to record pain on a scale from '0' to '10'. '0' is no pain and '10' is the highest level of pain.

    Time frame: 48 weeks after inpatient hospitalisation

  2. Number of sick days from T0 to T3 (headache diary)

    Time frame: 48 weeks after inpatient hospitalisation

  3. - Number of painkillers/month (headache diary)

    Time frame: 48 weeks after inpatient hospitalisation

  4. Headache Disability Index (HDI)

    HDI measure the impact of headache disorders on quality of life. The HDI is a 27-item questionnaire. The first two questions relate to frequency (once per month; more than once per month but less than four per month; more than once per week) and intensity ('mild', 'moderate' and 'severe'). The remaining 25 questions are designed to assess the quality of life affected by headache. Each question can be scored from 0 to 4 points. A total score of '10-28' indicates mild disability, '30-48' is moderate, '50-68' is severe and '72' or more is complete disability.

    Time frame: 48 weeks after inpatient hospitalisation

  5. Short-Form Health Survey (SF-12)

    The Short-Form Health Survey 12 assesses the impact of health on an individual's daily life. The SF-12 theoretically ranges from '0' (lowest possible quality of life) to '100' (highest possible quality of life). The SF-12 measures disease-related quality of life using 12 items divided into 8 subscales. Higher scores indicate better quality of life.

    Time frame: 48 weeks after inpatient hospitalisation

  6. Hospital Anxiety and Depression Scale (HADS)

    Anxiety and depression are measured using the HADS. The questionnaire contains 14 items, 7 on the anxiety scale and 7 on the depression scale. Total scores on the HADS-A (anxiety) and HADS-D (depression) scales range from '0-21', with higher scores indicating higher levels of anxiety/depression. Scores of '0-7' per HADS subscale (HADS-A/D) are considered 'normal', '8-10' as 'mild', scores above '11' as severe (up to '14' 'moderate', '15-21' 'severe').

    Time frame: 48 weeks after inpatient hospitalisation

  7. Flourishing Scale (FS)

    Subjective well-being is assessed using the Flourishing Scale. This consists of 8 socio-psychological well-being items that can be scored on a scale from '1' to '7'. The possible range of the total score is from '8' (lowest possible score) to '56' (highest possible score). A high score corresponds to a person with many psychological resources and strengths.

    Time frame: 48 weeks after inpatient hospitalisation

  8. Perception Stress Scale (PSS-10)

    Perceived stress is measured using two scales (helplessness and self-efficacy) based on 10 items. The scales can be scored from '0' (never) to '5' (very often). The total score is calculated as the sum of the helplessness scale items and the sum of the inverted self-efficacy scale items. Higher scores indicate higher levels of stress.

    Time frame: 48 weeks after inpatient hospitalisation

Other outcomes

  1. - Causation and Intensity of Adverse events (AEs)

    negative side effects

    Time frame: 12 months after inpatient hospitalisation

  2. Medical service use figures

    Previous experience, use and expectations of integrative and complementary therapies will also be assessed using socio-demographic data.

    Time frame: 48 weeks after inpatient hospitalisation

  3. Work ability

    Work ability is recorded as part of the socio-demographic data and can be rated on a scale from '0' (total inability to work) to '10' (best possible ability to work).

    Time frame: 48 weeks after inpatient hospitalisation

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Jan 2030, 60 months later.

Of 132 non-industry observational studies under Migraine Disorders, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 72. This study's planned 60 months is above that.

Counting every sponsor, half of 160 studies reached it within 27 months; a quarter within 12 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2024
First posted
Jan 9, 2025
StartEst.
Jan 1, 2025
Primary completionEst.
Jan 1, 2030
CompletionEst.
Jan 1, 2031
Last update
Jan 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06764914
Lead sponsor
Kliniken Essen-Mitte
Responsible party
Sponsor
First posted
Jan 9, 2025
Start date
Jan 1, 2025 (estimated)
Primary completion
Jan 1, 2030 (estimated)
Completion
Jan 1, 2031 (estimated)
Last update
Jan 9, 2025

Study contacts

Wiebke Kohl-Heckl, Dr. med.
Contact
W.Kohl-Heckl@kem-med.com
25058 ext. +49 201 174
Verena Boventer
Contact
V.Boventer@kem-med.com
39061 ext. +49 201 174
Petra Voiß, PD Dr. med.
study chair · Evang. Kliniken Essen-Mitte, Clinic for Integrative Oncology & Supportivemedicine

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion